ALX Oncology Holdings Inc.

58.76+0.8100+1.40%Vol 122.00K1Y Perf 94.43%
Apr 13th, 2021 14:50 DELAYED
BID58.41 ASK58.77
Open58.44 Previous Close57.95
Pre-Market- After-Market-
 - -%  - -
Target Price
99.00 
Analyst Rating
— — 0.00
Potential %
71.34 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     60.90
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap2.36B 
Earnings Rating
Price Range Ratio 52W %
34.38 
Earnings Date
18th Mar 2021

Today's Price Range

55.7559.53

52W Range

28.01117.45

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-22.33%
1 Month
-24.89%
3 Months
-29.48%
6 Months
60.08%
1 Year
94.43%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALXO58.760.81001.40
AAPL134.493.25002.48
GOOG2 269.1114.32000.64
MSFT258.232.32000.91
XOM55.660.16000.29
WFC39.85-0.9200-2.26
JNJ159.15-2.4900-1.54
FB312.010.47000.15
GE13.45-0.1400-1.03
JPM154.61-1.3400-0.86
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.36-0.48-33.33
Q03 2020-0.37-0.355.41
Q02 2020-0.29-4.28-1 375.86
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.36
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume122.00K
Shares Outstanding40.13M
Trades Count2.27K
Dollar Volume23.72M
Avg. Volume240.61K
Avg. Weekly Volume127.83K
Avg. Monthly Volume325.54K
Avg. Quarterly Volume253.00K

ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock closed at 57.95 per share at the end of the most recent trading day (a -9.13% change compared to the prior day closing price) with a volume of 145.85K shares and market capitalization of 2.36B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. ALX Oncology Holdings Inc. CEO is Jaume Pons.

The one-year performance of ALX Oncology Holdings Inc. stock is 94.43%, while year-to-date (YTD) performance is -32.77%. ALXO stock has a five-year performance of %. Its 52-week range is between 28.01 and 117.45, which gives ALXO stock a 52-week price range ratio of 34.38%

ALX Oncology Holdings Inc. currently has a PE ratio of -66.10, a price-to-book (PB) ratio of 6.74, a price-to-sale (PS) ratio of 4 412.47, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.81%, a ROC of -14.15% and a ROE of -28.36%. The company’s profit margin is -%, its EBITDA margin is -1 405.90%, and its revenue ttm is $527.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from ALX Oncology Holdings Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. ALX Oncology Holdings Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ALX Oncology Holdings Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ALX Oncology Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ALX Oncology Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ALX Oncology Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.24, ATR14 : 7.18, CCI20 : -145.26, Chaikin Money Flow : -0.28, MACD : -3.30, Money Flow Index : 55.41, ROC : -7.78, RSI : 38.05, STOCH (14,3) : 1.06, STOCH RSI : 0.09, UO : 25.59, Williams %R : -98.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ALX Oncology Holdings Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.

CEO: Jaume Pons

Telephone: +1 650 466-7125

Address: 866 Malcolm Road, Burlingame 94010, CA, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

64%36%

News

Stocktwits